Position in NVS
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$103,905
-$246,961 QoQ
Shares Held
663
-71.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,372
of 1,603 holders
Holding Since
Sep 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Community Financial Services Group, LLC holds $29,647,618 across 10 Drug Manufacturers - General names. NVS ranks #7 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
12,614 | $15,129,610 | |
| 2 | ABBV |
AbbVie Inc.
|
33,749 | $8,492,598 | |
| 3 | MRK |
Merck & Co., Inc.
|
29,385 | $3,775,972 | |
| 4 | JNJ |
Johnson & Johnson
|
5,518 | $1,401,406 | |
| 5 | PFE |
Pfizer Inc
|
15,023 | $361,753 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
1,931 | $111,263 | |
| 7 | NVS |
Novartis AG
This page
|
663 | $103,905 | |
| 8 | AMGN |
Amgen Inc
|
279 | $101,031 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $103,905 | 663 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $350,866 | 2,297 | Shares | Defined | 2026-04-08 | |
| 2025-12-31 | $485,990 | 3,525 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $499,623 | 3,896 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $471,454 | 3,896 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $464,537 | 4,167 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $5,250,068 | 53,952 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $6,232,702 | 54,188 | Shares | Sole | 2024-10-21 | |
| 2024-06-30 | $5,637,269 | 52,952 | Shares | Sole | 2024-07-25 | |
| 2024-03-31 | $4,803,611 | 49,660 | Shares | Sole | 2024-04-23 | |
| 2023-09-30 | $855,929 | 8,403 | Shares | Sole | 2023-11-07 | |
| No filing history on record for this holder in this stock. | ||||||